Company Encyclopedia
View More
name
xinbang phar.
002390.SZ
Guizhou Xinbang Pharmaceutical Co., Ltd. manufactures and sells traditional Chinese medicine and other pharmaceutical products in China and internationally. The company cardiovascular and cerebrovascular, digestive system, endocrine, tumors and immunomodulatory drugs, blood system drugs, rheumatism and rheumatoid arthritis, urinary system, antipyretic and analgesic, cold medicine, gynecological medications, and anti-infective drugs. It also provides medical services.
3.157 T
002390.SZMarket value -Rank by Market Cap -/-

Financial Score

05/12/2025 Update
C
PharmaceuticalsIndustry
Industry Ranking125/223
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreD
    • ROE1.14%D
    • Profit Margin1.35%C
    • Gross Margin17.74%D
  • Growth ScoreD
    • Revenue YoY-7.57%D
    • Net Profit YoY-64.50%D
    • Total Assets YoY-3.43%D
    • Net Assets YoY-1.73%D
  • Cash ScoreC
    • Cash Flow Margin7434.41%A
    • OCF YoY-7.57%D
  • Operating ScoreB
    • Turnover0.66B
  • Debt ScoreA
    • Gearing Ratio18.83%A

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Xinbang Pharmaceutical released its performance for the first three quarters, with a net profit attributable to the parent company of 152 million yuan, a year-on-year decrease of 13.74%

    According to the Zhitong Finance APP, Xinbang Pharmaceutical released its third-quarter report for 2025. In the first three quarters, the company achieved operating revenue of 4.266 billion yuan, a year-on-year decrease of 6.55%. The net profit attributable to shareholders of the listed company was 152 million yuan, a year-on-year decrease of 13.74%. The net profit attributable to shareholders of the listed company after deducting non-recurring gains and losses was 157 million yuan, a year-on-year decrease of 10.50%

    Zhitong·
    SZ
    002390
    -0.25%
    Zhitong·
    SZ
    002390
    -0.25%

    Xinbang Pharmaceutical released its performance for the first half of the year, with a net profit attributable to the parent company of 107 million yuan, a decrease of 6.69%

    According to the Zhitong Finance APP, Xinbang Pharmaceutical released its semi-annual report for 2025, reporting an operating income of 2.845 billion yuan, a year-on-year decrease of 6.62%. The net profit attributable to shareholders of the listed company was 107 million yuan, a year-on-year decrease of 6.69%. The net profit attributable to shareholders of the listed company after deducting non-recurring gains and losses was 107 million yuan, a year-on-year decrease of 7.16%. The basic earnings per share were 0.0565 yuan

    Zhitong·
    SZ
    002390
    -0.25%
    Zhitong·
    SZ
    002390
    -0.25%

    Xinbang Pharmaceutical released its first-quarter performance, with a net profit attributable to the parent company of 41.2442 million yuan, a decrease of 29.89%

    Xinbang Pharmaceutical released its Q1 2025 performance, with operating revenue of 1.441 billion yuan, a year-on-year decrease of 8.93%; net profit attributable to the parent company of 41.2442 million yuan, a year-on-year decline of 29.89%; net profit excluding non-recurring gains and losses of 41.0754 million yuan, a year-on-year decrease of 30.16%; basic earnings per share of 0.02 yuan

    Zhitong·
    SZ
    002390
    -0.25%
    Zhitong·
    SZ
    002390
    -0.25%

    Xinbang Pharmaceutical released its 2024 annual performance, with a net profit attributable to the parent company of 101 million yuan, a year-on-year decrease of 64.70%

    Xinbang Pharmaceutical released its 2024 annual report, with operating revenue of 6.032 billion yuan, a year-on-year decrease of 6.63%; net profit attributable to the parent company was 101 million yuan, a year-on-year decrease of 64.70%. After deducting non-recurring gains and losses, the net profit was 165 million yuan, a year-on-year decrease of 38.29%. The basic earnings per share were 0.05 yuan, and it is proposed to distribute a cash dividend of 0.30 yuan for every 10 shares. The decline in net profit was mainly due to a decrease in revenue from the pharmaceutical distribution and medical services sectors, a decline in gross profit margin, and an increase in non-recurring gains and losses

    Zhitong·
    SZ
    002390
    -0.25%
    Zhitong·
    SZ
    002390
    -0.25%

    Xinbang Pharmaceutical responds to the acceptance of bribery case involving its controlling subsidiary and shareholders: currently verifying

    According to the WeChat official account of the Kaiyang County People's Court, on February 26, the Kaiyang County People's Court accepted the case of bribery by Guizhou Kekai Pharmaceutical Co., Ltd. and bribery by An Huailue. The 2023 financial report of Xinbang Pharmaceutical shows that Guizhou Kekai Pharmaceutical Co., Ltd. is a holding subsidiary of Xinbang Pharmaceutical, and An Ji is the actual controller of Xinbang Pharmaceutical, while An Huailue has a relationship of concerted action with the actual controller. Public information indicates that An Huailue and An Ji are father and daughter. The third quarterly report for 2024 shows that An Huailue holds 5.04% of Xinbang Pharmaceutical shares. On March 3, a reporter contacted the securities affairs representative hotline of Xinbang Pharmaceutical, and the staff stated that they had seen the news in the morning and were verifying it, "We will check according to relevant regulations to see if it meets the announcement requirements."

    USHK News·
    SZ
    002390
    -0.25%
    USHK News·
    SZ
    002390
    -0.25%
    © 2025 Longbridge｜Disclaimer